Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.91
-0.0400-1.36%
Post-market: 2.960.0500+1.72%19:47 EDT
Volume:671.33K
Turnover:1.97M
Market Cap:331.74M
PE:-2.14
High:3.00
Open:2.97
Low:2.90
Close:2.95
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:74.34M
Volume Ratio:0.74
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3615
EPS(LYR):-1.3971
ROE:-35.33%
ROA:-20.27%
PB:0.95
PE(LYR):-2.08

Loading ...

Perspective Therapeutics Announces Acceptance of Vmt-α-net Data for Oral Presentation at the Esmo Congress 2026

THOMSON REUTERS
·
Jul 18

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

GlobeNewswire
·
Jul 18

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jul 11

Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-founder Schultz Moves to Advisor Role

Reuters
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jul 06

Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline

TIPRANKS
·
Jul 02

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jun 27

Perspective Therapeutics doses first meningioma patient in Phase 1/2a trial of [212Pb]VMT-α-NET

Reuters
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed With [212PB]Vmt-Α-Net in the Meningioma Cohort of a Phase 1/2a Study

THOMSON REUTERS
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

GlobeNewswire
·
Jun 03

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

TIPRANKS
·
Jun 01

H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Jun 01

Perspective Therapeutics shareholders elect six directors at annual meeting

Reuters
·
May 28

Perspective Therapeutics reports 29% response rate in [212Pb]VMT01 melanoma cohort 3.0 mCi trial

Reuters
·
May 22

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

GlobeNewswire
·
May 22

Perspective Therapeutics doses first patients in two Phase 1/2a studies

TIPRANKS
·
May 18

Perspective Therapeutics doses first patient in new VMT-α-NET Phase 1/2a cohort

Reuters
·
May 18

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

THOMSON REUTERS
·
May 18

LifeSci Capital Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 16

Perspective Therapeutics price target lowered to $6 from $7 at BofA

TIPRANKS
·
May 13